Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuropathology of vigabatrin.

Literature DB >> 2757908

Neuropathology of vigabatrin.

Abstract

1. Neuropathological changes in experimental animals have been observed with vigabatrin treatment in mice, rats and dogs. 2. These changes have comprised intramyelinic oedema which is reversible on cessation of treatment. 3. In human studies so far, no intramyelinic oedema has been noted. It is not clear whether humans will show the neurotoxicity observed in animals; close monitoring of patients is indicated.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2757908 PMCID： PMC1379678 DOI： 10.1111/j.1365-2125.1989.tb03460.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

4 in total

1. Hexachlorophene neuropathy in rats.

Authors: J Towfighi; N K Gonatas; L McCree
Journal: Lab Invest Date: 1973-10 Impact factor: 5.662

2. Isonicotinic acid hydrazide-induced spongy degeneration of the white matter in the brains of Pekin ducks.

Authors: W W Carlton; G Kreutzberg
Journal: Am J Pathol Date: 1966-01 Impact factor: 4.307

3. Fine structure and electrolyte analyses of cerebral edema induced by alkyl tin intoxication.

Authors: F P Aleu; R Katzman; R D Terry
Journal: J Neuropathol Exp Neurol Date: 1963-07 Impact factor: 3.685

4. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats.

Authors: W H Butler; G P Ford; J W Newberne
Journal: Toxicol Pathol Date: 1987 Impact factor: 1.902

4 in total

13 in total

1. Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors: Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal: J Child Neurol Date: 2011-02-22 Impact factor: 1.987

2. Visual field defects associated with vigabatrin therapy.

Authors: M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal: J Neurol Neurosurg Psychiatry Date: 1999-12 Impact factor: 10.154

Review 3. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors: S M Grant; R C Heel
Journal: Drugs Date: 1991-06 Impact factor: 9.546

4. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.

Authors: R Okeda; M Shibutani; T Matsuo; T Kuroiwa; R Shimokawa; T Tajima
Journal: Acta Neuropathol Date: 1990 Impact factor: 17.088

Review 5. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors: J Srinivasan; A Richens
Journal: Drug Saf Date: 1994-05 Impact factor: 5.606

Review 6. Transient focal lesion in the splenium of the corpus callosum: MR imaging with an attempt to clinical-physiopathological explanation and review of the literature.

Authors: M Conti; A Salis; C Urigo; L Canalis; S Frau; G C Canalis
Journal: Radiol Med Date: 2007-09-20 Impact factor: 3.469

7. Effects of vigabatrin on evoked potentials in epileptic patients.

Authors: V Cosi; R Callieco; C A Galimberti; R Manni; A Tartara; J Mumford; E Perucca
Journal: Br J Clin Pharmacol Date: 1989 Impact factor: 4.335

Review 8. Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors: P N Patsalos; J W Sander
Journal: Drug Saf Date: 1994-07 Impact factor: 5.606

9. Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.

Authors:
Journal: Ital J Neurol Sci Date: 1992-12

10. Treatment of refractory complex partial seizures: role of vigabatrin.

Authors: Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal: Neuropsychiatr Dis Treat Date: 2009-10-12 Impact factor: 2.570